This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Neovasc 将来の成長

Future 基準チェック /06

主要情報

n/a

収益成長率

n/a

EPS成長率

Medical Equipment 収益成長	16.7%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	10 Feb 2023

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:G5Z - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2023	10	-23	N/A	N/A	1
12/31/2022	4	-41	-25	-25	N/A
9/30/2022	3	-34	-24	-24	N/A
6/30/2022	3	-33	-25	-25	N/A
3/31/2022	3	-33	-26	-25	N/A
12/31/2021	3	-25	-27	-27	N/A
9/30/2021	2	-23	-30	-29	N/A
6/30/2021	2	-26	-31	-31	N/A
3/31/2021	2	-27	-32	-31	N/A
12/31/2020	2	-29	-30	-29	N/A
9/30/2020	2	-37	-29	-29	N/A
6/30/2020	2	-33	-27	-27	N/A
3/31/2020	2	-31	-25	-25	N/A
12/31/2019	2	-35	-24	-24	N/A
9/30/2019	2	-11	-24	-24	N/A
6/30/2019	2	-20	-23	-23	N/A
3/31/2019	2	-61	-24	-24	N/A
12/31/2018	2	-108	-23	-23	N/A
9/30/2018	2	-125	-141	-141	N/A
6/30/2018	3	-115	-140	-140	N/A
3/31/2018	4	-71	-138	-138	N/A
12/31/2017	5	-22	-139	-139	N/A
9/30/2017	7	19	-22	-21	N/A
6/30/2017	9	-5	-29	-28	N/A
3/31/2017	9	-83	-36	-35	N/A
12/31/2016	10	-86	-40	-40	N/A
9/30/2016	9	-131	N/A	-39	N/A
6/30/2016	8	-110	N/A	-35	N/A

アナリストによる今後の成長予測

収入対貯蓄率: Insufficient data to determine if G5Z's forecast earnings growth is above the savings rate (0.2%).

収益対市場: Insufficient data to determine if G5Z's earnings are forecast to grow faster than the German market

高成長収益: Insufficient data to determine if G5Z's earnings are expected to grow significantly over the next 3 years.

収益対市場: Insufficient data to determine if G5Z's revenue is forecast to grow faster than the German market.

高い収益成長: Insufficient data to determine if G5Z's revenue is forecast to grow faster than 20% per year.

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: Insufficient data to determine if G5Z's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Neovasc 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

ShockWave Medical, Inc. (NasdaqGS:SWAV) entered into a definitive agreement to acquire Neovasc Inc. (TSX:NVCN) from Strul Medical Group LLC and others for $75.04 million.

Neovasc Announces Progress on COSIRA-II Clinical Trial

Third quarter 2022 earnings released: US$3.00 loss per share (vs US$2.79 loss in 3Q 2021)

Insufficient new directors

Insufficient new directors

Neovasc Inc. to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

Neovasc Inc. Announces Positive Clinical Data at Transcatheter Cardiovascular Therapeutics Conference and Provides Update on Mitral Valve Program

Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina

Independent Director recently bought €76k worth of stock

Second quarter 2022 earnings released: US$3.29 loss per share (vs US$3.35 loss in 2Q 2021)

Neovasc Inc. to Report Q2, 2022 Results on Aug 11, 2022

Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

First quarter 2022 earnings released: US$3.75 loss per share (vs US$1.11 loss in 1Q 2021)

Neovasc Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Neovasc Inc. to Report Q4, 2021 Results on Mar 10, 2022

Neovasc Inc., Annual General Meeting, Apr 12, 2022

German Institute for the Hospital Remuneration System Awards Neovasc, Inc.'s Reducer™ NUB Status 1 Designation for 2022

Neovasc Inc. Announces the Publication of Cost-Effectiveness Studies Supporting the Use of the Neovasc Reducer

Neovasc Inc. Announces Complete Dismissal of Securities Class Action Complaint with Prejudice

Neovasc Inc. Announces Case Series of First U.S. Reducer Implants Published in Peer-Reviewed Journal

Neovasc Announces First Patient Enrollment in Cosira-II Trial

Chief Operating Officer recently bought €70k worth of stock

The National Institute for Health and Care Excellence of the United Kingdom Provides Positive Guidance for Neovasc Reducer System

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.51 loss in 3Q 2020)

Independent Director recently bought €65k worth of stock

Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.81 loss in 2Q 2020)

Independent Director recently bought €73k worth of stock

Neovasc Inc Provides Corporate Update

Neovasc Reducer System Receives First National Reimbursement in Europe

Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Neovasc Inc. Provides Update on German Litigation

Neovasc Announces First Patient Enrollment in COSIMA Trial

First quarter 2021 earnings released: US$0.04 loss per share (vs US$0.38 loss in 1Q 2020)

Full year 2020 earnings released: US$1.72 loss per share (vs US$5.40 loss in FY 2019)

Revenue misses expectations

Neovasc Inc. to Report Q4, 2020 Results on Mar 11, 2021

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

New 90-day high: €1.25

American Medical Association Issues New CPT Code for Neovasc Reducer Procedure

New 90-day high: €1.10

Neovasc Inc. Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer(TM)

Zhang Investor Law Alerts Investors to Upcoming Deadline in Securities Class Action Lawsuit Against Neovasc Inc

Pomerantz LLP Announces A Class Action Lawsuit Filed Against Neovasc Inc. and Certain of Its Officers

Neovasc Announces First Neovasc Reducer Implants in France

Neovasc Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Neovasc Inc. has completed a Follow-on Equity Offering in the amount of $6.10681 million.

Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

New 90-day low: €0.56

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Neovasc Inc

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Neovasc Inc. (NVCN) Investors

Pawar Law Group Announces A Securities Class Action Lawsuit Against Neovasc Inc

New 90-day low: €0.61

Third quarter 2020 earnings released: US$0.51 loss per share

Revenue beats expectations

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Neovasc Inc

New 90-day low: €1.64

Neovasc, Inc. Treats 300 Patient in Germany with the Neovasc Reducer

Neovasc Inc. has completed a Follow-on Equity Offering in the amount of $12.581842 million.

New 90-day low - €1.90

Earnings released

Neovasc Inc. to Report Q2, 2020 Results on Aug 06, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘